18 terminated. 18 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 18 | Terminated 18 |
Follow Vancomycin: new trials by email Literature Review of Vancomycin trials Research Report on Vancomycin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparing Oral Versus Parenteral Antimicrobial Therapy Amoxicillin, amoxicillin-clavulanate, cefadroxil, cefpodoxime, cefalexin, ciprofloxacin, delafloxacin, doxycycline, levofloxacin, linezolid, Ampicillin, ampicillin-sulbactam, cefazolin, cefepime, ceftaroline, ceftazidime, ceftazidime-avibactam, dalbavancin, daptomycin, ertapenem - Endovascular Infection, Bone and Joint Infection | Phase 4 | Terminated | West Virginia University | 94 | 2023-08-04 | 2025-08-26 |
| Postoperative Antibiotic Management Duration Following Surgery for Intravenous Drug Abuse (IVDA) Endocarditis (OPTIMAL) Amoxycillin, Cefalexin, Dicloxacillin, Linezolid, Levofloxacin, Rifampicin, Ampicillin, Oxacillin, Vancomycin, Daptomycin, Ceftriaxone, Cefepime, Ceftaroline - Endocarditis | Phase 4 | Terminated | West Virginia University | 5 | 2022-03-16 | 2026-05-05 |
| Early Antibiotics After Aspiration in ICU Patients Ceftriaxone, Amoxicillin clavulanic acid, Cefepime - Aspiration, Aspiration Pneumonia | Phase 4 | Terminated | UConn Health | 5 | 2021-11-30 | 2025-12-30 |
| Safety and Outcomes Associated With Continuous Versus Intermittent Infusion Vancomycin Vancomycin CI, Vancomycin II - Infection | Phase 4 | Terminated | Wake Forest University Health Sciences | 8 | 2021-03-03 | 2024-02-14 |
| Oral Vancomycin for Secondary Prophylaxis of Clostridium Difficile Infection (CDI) Oral Vancomycin, Placebo - Clostridium Difficile Infection, Clostridium Difficile Infection Recurrence | Phase 4 | Terminated | University of South Florida | 26 | 2019-09-01 | 2023-04-21 |
| Oral Vancomycin for Preventing Clostridium Difficile Recurrence Oral Vancomycin, Placebo - Clostridium Difficile Infection | Phase 4 | Terminated | Rochester General Hospital | 65 | 2017-06-08 | 2021-04-26 |
| C1-inhibitor in Allergic ASThma Patients C1-inhibitor, Saline, Antibiotics - Asthma | Phase 4 | Terminated | T. van der Poll | 37 | 2016-11-16 | 2020-06-24 |
| Optimal Treatment for Recurrent Clostridium Difficile Fidaxomicin, Vancomycin with Taper/Pulse, Vancomycin - Clostridium, Difficile | Phase 4 | Terminated | VA Office of Research and Development | 308 | 2016-02-19 | 2026-08-21 |
| Aerosolized Antibiotics in the Treatment of Ventilator Associated Pneumonia Aerosolized Tobramycin or Vancomycin, Aerosolized Placebo - Pneumonia, Ventilator-Associated | Phase 4 | Terminated | Wright State University | 16 | 2015-06-01 | 2023-05-31 |
| Local Application of Vancomycin Powder in Grade I-IIIA Open Fractures Vancomycin - Fractures, Open, Surgical Wound Infection | Phase 4 | Terminated | University of Tennessee | 11 | 2015-03-01 | 2018-11-29 |
| Use Of Oral Fidaxomicin Vs. Oral Vancomycin For Clostridium Difficile Infection In Patients With Spinal Cord Injury Fidaxomicin 200 mg, Placebo, Vancomycin - Clostridium Difficile, Spinal Cord Injury | Phase 4 | Terminated | Baylor College of Medicine | 12 | 2014-02-01 | 2016-10-13 |
| A Post-marketing, Blinded Study to Investigate How Effective Fidaxomicin is Compared to Vancomycin in the Sustained Cure of Clostridium Difficile Infection in Adults That Are Receiving Therapy to Suppress the Immune System Fidaxomicin, Vancomycin, Placebo - Clostridium Difficile | Phase 4 | Terminated | Astellas Pharma Europe Ltd. | 12 | 2012-11-29 | 2020-01-13 |
| Safety and Efficacy of Strategy to Prevent Drug-Induced Nephrotoxicity in High-Risk Patients Vancomycin, Ceftaroline, Daptomycin - Health Care Associated Pneumonia, Osteomyelitis/Septic Arthritis | Phase 4 | Terminated | Henry Ford Health System | 100 | 2011-10-01 | 2023-05-03 |
| Vancomycin Versus Daptomycin for the Treatment of Methicillin-resistant Staphylococcus Aureus Bacteremia Due to Isolates With High Vancomycin Minimum Inhibitory Concentrations (MICs) Vancomycin, Daptomycin - Bacteremia | Phase 4 | Terminated | St. John Health System, Michigan | 11 | 2011-06-01 | 2014-02-10 |
| Daptomycin Use for Antimicrobial Prophylaxis in Methicillin Resistant Staphylococcus Aureus (MRSA) Colonized Adult Patients Undergoing Primary Elective Hip, Knee, or Shoulder Arthroplasty Daptomycin, Vancomycin - Staphylococcal Infections, Methicillin-resistant Staphylococcus Aureus | Phase 4 | Terminated | Mountain Home Research & Education Corporation | 28 | 2010-10-01 | 2014-02-03 |
| Outpatient Treatment of Gram Positive Wound Infections in the Diabetic Foot: A Pharmaco-economic Comparison of Daptomycin vs. Vancomycin Based Regimens Cubicin, Vancomycin - Diabetic Foot | Phase 4 | Terminated | Clinical Alliance for Research & Education - Infectious Diseases, LLC. | 6 | 2010-08-01 | 2013-09-10 |
| Study Comparing Cubicin With Vancomycin in Treatment of Participants With Complicated Skin and Skin Structure Infections in a Home Infusion Setting Daptomycin, Vancomycin - Complicated Skin or Skin Structure Infection | Phase 4 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 80 | 2010-07-15 | 2018-12-26 |
| Study of Daptomycin Safety and Efficacy for Complicated Skin and Skin Structure Infections (cSSSI) and Bacteremia in Renal Impairment Vancomycin, Daptomycin, Semi-Synthetic Penicillin - Complicated Skin and Skin Structure Infections, S. Aureus Bacteremia | Phase 4 | Terminated | Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 92 | 2010-04-19 | 2018-09-05 |
Bacteremia (2) · Clostridium Infections (2) · Endocarditis (2) · Infections (2) · Pneumonia, Ventilator-Associated (2) · Staphylococcal Infections (2) · Angioedemas, Hereditary (1) · Arthritis, Infectious (1) · Asthma (1) · Diabetic Foot (1) · Fractures, Open (1) · Osteomyelitis (1) · Pneumonia, Aspiration (1) · Recurrence (1) · Renal Insufficiency (1)
Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (2) · West Virginia University (2) · Astellas Pharma Europe Ltd. (1) · Baylor College of Medicine (1) · Clinical Alliance for Research & Education - Infectious Diseases, LLC. (1) · Henry Ford Health System (1) · Mountain Home Research & Education Corporation (1) · Rochester General Hospital (1) · St. John Health System, Michigan (1) · T. van der Poll (1) · UConn Health (1) · University of South Florida (1) · University of Tennessee (1) · VA Office of Research and Development (1) · Wake Forest University Health Sciences (1)
United States (15) · Austria (1) · Denmark (1) · France (1) · Germany (1) · Greece (1) · Netherlands (1) · Poland (1) · Puerto Rico (1) · Spain (1)
Arif R. Sarwari, MD, MSc, MBA (1) · Brandon Oto (1) · Dale N Gerding, MD (1) · Dirk W Kiner, MD (1) · Donald Poretz, MD (1) · Ellie Hershberger, Pharm.D. (1) · John K. Bini, MD (1) · John Williamson, PharmD (1) · Jose Vazquez, M.D. (1) · Joy J. Juskowich, MD (1) · Maryrose R Laguio-Vila, MD (1) · Mindy Sampson, DO (1) · Paula Bokesch, MD (1) · Priti Parikh, PhD (1)